Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Nickolas Papadopoulos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7135-7451; OpenAlex author ID A5037021577; NIH RePORTER profile ID 9901413. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
1
Labs led
0
Collaborators
66
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 grant

Papers 9

  1. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1. Co-author DOI 10.7554/elife.94488↗
  2. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Co-author DOI 10.7554/elife.94488.3↗
  3. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  4. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Co-author DOI 10.1038/ng.3764↗
  5. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  6. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Co-author DOI 10.1007/s10689-014-9755-y↗
  7. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Co-author DOI 10.1158/1078-0432.ccr-14-2600↗
  8. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Co-author DOI 10.1158/0008-5472.can-14-0734↗
  9. ATM mutations in patients with hereditary pancreatic cancer. Co-author DOI 10.1158/2159-8290.cd-11-0194↗

Grants 1

  1. Improving Management of patients at High Risk of Pancreatic Cancer R01CA299421↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alison P. Klein · 4 shared papers, 1 shared grant, 2012–2026 · strength 1.41
  2. Bert Vogelstein · 9 shared papers, 2012–2025 · strength 0.72
  3. Kenneth W. Kinzler · 9 shared papers, 2012–2025 · strength 0.72
  4. Marco Dal Molin · 3 shared papers, 2015–2025 · strength 0.45
  5. Surojit Sur · 2 shared papers, 2025 · strength 0.41
  6. Jordina Rincón-Torroella · 2 shared papers, 2025 · strength 0.41
  7. Nilofer Saba Azad · 2 shared papers, 2025 · strength 0.41
  8. Ralph H. Hruban · 6 shared papers, 2012–2017 · strength 0.24
  9. Christopher Lee Wolfgang · 4 shared papers, 2014–2019 · strength 0.18
  10. Laura DeLong Wood · 3 shared papers, 2015–2017 · strength 0.13
  11. Nicholas Jason Roberts · 3 shared papers, 2012–2016 · strength 0.11
  12. James R. Eshleman · 3 shared papers, 2012–2016 · strength 0.11
  13. Anne Marie Lennon · 2 shared papers, 2014–2019 · strength 0.10
  14. Michael Goggins · 3 shared papers, 2012–2016 · strength 0.10
  15. Alvin P. Makohon-Moore · 2 shared papers, 2016–2017 · strength 0.09
  16. Christine A. Iacobuzio–Donahue · 2 shared papers, 2016–2017 · strength 0.09
  17. Alexis L. Norris · 2 shared papers, 2015–2016 · strength 0.08
  18. Joseph M. Herman · 2 shared papers, 2014–2016 · strength 0.07
  19. David Goldstein · 1 shared paper, 2019 · strength 0.07
  20. Benjamin N. J. Thomson · 1 shared paper, 2019 · strength 0.07
  21. Ben J. Lawrence · 1 shared paper, 2019 · strength 0.07
  22. Andrew Mark Haydon · 1 shared paper, 2019 · strength 0.07
  23. Adnan M. Nagrial · 1 shared paper, 2019 · strength 0.07
  24. Matthew Burge · 1 shared paper, 2019 · strength 0.07
  25. Niall Christopher Tebbutt · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.